You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-BRCA2 (BRCA2) Antibodies

Full name:
anti-Breast Cancer 2, Early Onset Antibodies (BRCA2)
On www.antibodies-online.com are 87 Breast Cancer 2, Early Onset (BRCA2) Antibodies from 23 different suppliers available. Additionally we are shipping BRCA2 Kits (24) and BRCA2 Proteins (2) and many more products for this protein. A total of 116 BRCA2 products are currently listed.
Synonyms:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
list all antibodies Gene Name GeneID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

Show all species

Show all synonyms

Most Popular Reactivities for anti-BRCA2 (BRCA2) Antibodies

Select your species and application

anti-Mouse (Murine) BRCA2 Antibodies:

anti-Human BRCA2 Antibodies:

anti-Rat (Rattus) BRCA2 Antibodies:

All available anti-BRCA2 Antibodies

Go to our pre-filtered search.

Top referenced anti-BRCA2 Antibodies

  1. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (p) - ABIN445491 : Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. in The Journal of biological chemistry 2000 (PubMed)
    Show all 2 references for ABIN445491

  2. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN445493 : Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001 (PubMed)
    Show all 2 references for ABIN445493

  3. Human Polyclonal BRCA2 Primary Antibody for IHC, ELISA - ABIN1533759 : Wooster, Bignell, Lancaster, Swift, Seal, Mangion, Collins, Gregory, Gumbs, Micklem: Identification of the breast cancer susceptibility gene BRCA2. in Nature 1996 (PubMed)
    Show all 2 references for ABIN1533759

  4. Human Polyclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN4285196 : Moeller, Yordy, Williams, Giri, Raju, Molkentine, Byers, Heymach, Story, Lee, Sturgis, Weber, Garden, Ang, Schwartz: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. in Clinical cancer research : an official journal of the American Association for Cancer Research 2011 (PubMed)

More Antibodies against BRCA2 Interaction Partners

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (show TP53 Antibodies) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (show PALB2 Antibodies) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (show PALB2 Antibodies) and Trp53 (show TP53 Antibodies) heterozygosity .

  2. Merit40 (show BABAM1 Antibodies) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (show FANCD2 Antibodies) mutation.

  3. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  4. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  5. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (show PARP1 Antibodies) inhibition.

  6. BRCA2-mediated sequestration of nuclear RAD51 (show RAD51 Antibodies) serves to prevent inappropriate DNA interactions.

  7. BRCA2 directly represses the expression of IFN-related genes

  8. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  9. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

  10. Results suggest that cellular levels of Brca2 and Rad51 (show RAD51 Antibodies) are mutually dependent on each other, and that low levels of these proteins provide selective pressure for reduction of p53 (show TP53 Antibodies), which permits cell growth

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Our aim was to set up a cost-effective and low time-consuming BRCA1-BRCA2 mutation detection workflow using the Ion Torrent PGM (show Vcan Antibodies) technology. A retrospective cohort of 40 patients with familial breast/ovarian cancer previously tested by Sanger sequencing and a prospective cohort of 72 patients (validation set) were analyzed.

  2. This is the largest study in Cyprus evaluating the prevalence and spectrum of BRCA1/2 mutations. Thirteen percent of the patients tested were positive for deleterious mutations which are within the range reported in other countries

  3. ubiquitination of RAD51 (show RAD51 Antibodies) hinders RAD51 (show RAD51 Antibodies)-BRCA2 interaction, while deubiquitination of RAD51 (show RAD51 Antibodies) facilitates RAD51 (show RAD51 Antibodies)-BRCA2 binding and RAD51 (show RAD51 Antibodies) recruitment and thus is critical for proper homologous recombination

  4. We studied effect of food on ABT-767 bioavailability in subjects with advanced BRCA1 or BRCA2 mutated solid tumors or high grade serous ovarian, primary peritoneal or fallopian tube cancer

  5. These results suggest that cytoplasmic dynein (show DYNC1H1 Antibodies) 1 binds to BRCA2 through the latter's centrosomal localization signal and BRCA2 mediates the cohesion between centrosomes during the S phase, potentially serving as a cell-cycle checkpoint.

  6. Results indicate that aberrant splicing is especially prevalent in breast cancer 2 protein (BRCA2) exons 17 and 18.

  7. BRCA2 mutation carriers are at increased risk developing insulin (show INS Antibodies) resistance and type-II diabetes mellitus; have an altered expression of circulating proteins associated with venous thrombo-embolism (Review)

  8. BRCA2 reversion mutation is associated with resistance to PARP (show COL11A2 Antibodies) inhibitor-based therapy in a pancreatic ductal adenocarcinoma.

  9. BRCA1/2-associated EOC patients with a previous BC have a worse outcome.

  10. By monitoring DNA double-strand breaks mis (show AMH Antibodies)-repair using a sensitive bioassay, it was found that depletion of homologous recombination proteins, including BRCA2, BRCA1 or RPA1 (show RPA1 Antibodies), resulted in a distinct mutational signature associated with significant increases in break-induced mutation frequencies.

BRCA2 Antigen Profile

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) antibody
  • breast cancer 2, early onset (brca2) antibody
  • breast cancer 2 (Brca2) antibody
  • breast cancer 2, early onset (Brca2) antibody
  • AI256696 antibody
  • AW045498 antibody
  • BRCA2 antibody
  • BRCC2 antibody
  • BROVCA2 antibody
  • FACD antibody
  • FAD antibody
  • FAD1 antibody
  • FANCB antibody
  • FANCD antibody
  • FANCD1 antibody
  • GLM3 antibody
  • PNCA2 antibody
  • RAB163 antibody

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
Selected quality suppliers for anti-BRCA2 (BRCA2) Antibodies
Did you look for something else?